Table 1.
SARS-CoV and -CoV-2 Mpro inhibitors in clinical trial.
| Name | Clinical stage | Clinical trial identifier | Sponsor |
|---|---|---|---|
| ensitrelvir (S-217622) (Figure 15) | Approved in Japan | NCT05897541, NCT05305547, NCT05605093 | Shionogi Inc., University of Minnesota |
| STI-1558 | Phase I/III | NCT05523739, NCT05716425 | Zhejiang ACEA Pharmaceutical Co. Ltd. |
| pomotrelvir (PBI-0451) | Phase II | NCT05543707 | Pardes Biosciences, Inc. |
| EDP-235 | Phase II | NCT05616728 | Enanta Pharmaceuticals, Inc. |
| ASC11 | Phase I | NCT05718518 | Ascletis Pharmaceuticals Co., Ltd. |
| HS-10517 | Phase II | NCT05779579 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| PF-07304814 (Figure 4) | Phase I | NCT04627532, NCT04535167, NCT05050682 | Pfizer |
| nirmatrelvir (Figure 6) /ritonavir | Approved worldwide | NCT05668091, NCT05576662 | Harlan M Krumholz / Stanford University |
| montelukast | Phase II | NCT04718285 | Bahcesehir University |
| masitinib (AB1010) (Figure 16) | Phase II | NCT05047783 | AB Science |